Together, the additional treatment of tumor-bearing mice with either anti-TIGIT or anti-PD-L1 augmented the antitumor effects of the anti-GD2 immunotherapy with DB, with superior effects in the “DB + anti-PD-L1” experimental group. This evidence concerns the gene TIGIT and neoplasm.